Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00728780

Enrollment

Registered

2008-08-06

Start date

2008-08-31

Completion date

Unknown

Last updated

2012-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Events, Pharmacokinetic Variables

Keywords

Adverse events, Pharmacokinetic variables

Brief summary

The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.

Interventions

DRUGABT-143

once

DRUGABT-335 and rosuvastatin

once

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Signed informed consent * Condition of good health

Exclusion criteria

* Currently enrolled in another study * Females who are pregnant or breast feeding

Design outcomes

Primary

Measure	Time frame
Adverse events and safety laboratory assessments	7 days
Pharmacokinetic parameters	7 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026